While keeping in mind that an optimal therapeutic for non-proliferative diabetic retinopathy would halt diabetes-mediated inflammation, oxidative stress, and VEGF production, and cease neural cell dysfunction and vascular impairment, we decided to investigate the efficacy of XMD8-92 as a novel therapeutic for non-proliferative diabetic retinopathy. This evidence concerns the gene VEGFA and proliferative diabetic retinopathy.